16305 36TH AVENUE N, MINNEAPOLIS, MN
Annual Report to Security Holders
Financial Results, Press Release
Changes in Board, Management or Compensation, Reg. FD
Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FY 2025
Q3
Q2
Q1
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Form D Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus